The WT1 cancer vaccine has recently received Fast Track designation from the Food and Drug Administration. Targeting the WT1 protein, this vaccine is set to become the first FDA approved second-line treatment for mesothelioma, meaning it would act to help prevent reoccurrence of the disease following first-line treatments such as chemotherapy, radiation, and surgery. In clinical trials, patients receiving the WT1 vaccine saw an average 8.2 month increase in survival rates, coming in at 24.8 months as opposed to the average 16.6 for those not receiving the vaccine.
Fast Track designation is granted by the FDA in cases where new medical developments address an unmeet need for the treatment of a deadly disease. There are currently no second-line therapies for mesothelioma, making WT1 a potential game-changer in improving the prognosis of mesothelioma patients. The FDA typically takes 10 or more years to approve a drug. With Fast Track designation, it is possible that WT1 could be available within a year of trial completion. A multicenter phase III trial is set to begin in early 2017.
New mesothelioma treatments offer great hope to the thousands of men and women who are diagnosed with this deadly form of cancer every year. However, like all mesothelioma therapies, it is likely that WT1 will be costly. This is but one of the reasons it is important to discuss your diagnosis with New York mesothelioma attorney Joseph Williams. Attorney Williams has the resources, dedication, and practical experience needed to handle these delicate and complex cases. He is prepared to take your case and fight for your rights, helping you secure the compensation you will need to receive the most effective treatments available.
If you have been diagnosed with mesothelioma in New York City or surrounding areas, please use our online contact form or call 855-575-MESO (6376) to schedule a free consultation with Attorney Williams today.